Mustang Bio (NASDAQ:MBIO) Issues Earnings Results

Posted by Don Miller on Nov 8th, 2025

Mustang Bio (NASDAQ:MBIO – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.07) earnings per share (EPS) for the quarter, FiscalAI reports.

Mustang Bio Trading Down 3.2%

Shares of NASDAQ:MBIO opened at $1.22 on Friday. The stock has a market cap of $8.83 million, a PE ratio of -0.54 and a beta of 2.30. The stock’s fifty day simple moving average is $1.53 and its two-hundred day simple moving average is $1.51. Mustang Bio has a 1-year low of $0.89 and a 1-year high of $21.95.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Mustang Bio stock. Anson Funds Management LP acquired a new stake in Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 45,716 shares of the company’s stock, valued at approximately $57,000. Anson Funds Management LP owned about 1.04% of Mustang Bio as of its most recent filing with the SEC. Institutional investors and hedge funds own 9.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on MBIO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mustang Bio in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Mustang Bio to a “hold” rating in a report on Friday, July 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

View Our Latest Report on Mustang Bio

Mustang Bio Company Profile

(Get Free Report)

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.